Cargando…
Lactobacillus reuteri Colonisation of Extremely Preterm Infants in a Randomised Placebo-Controlled Trial
Lactobacillus reuteri DSM 17938 supplementation reduces morbidities in very low birth weight infants (<1500 g), while the effect on extremely low birth weight infants (ELBW, <1000 g) is still questioned. In a randomised placebo-controlled trial (ClinicalTrials.gov ID NCT01603368), head growth,...
Autores principales: | Spreckels, Johanne E., Wejryd, Erik, Marchini, Giovanna, Jonsson, Baldvin, de Vries, Dylan H., Jenmalm, Maria C., Landberg, Eva, Sverremark-Ekström, Eva, Martí, Magalí, Abrahamsson, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190634/ https://www.ncbi.nlm.nih.gov/pubmed/33923278 http://dx.doi.org/10.3390/microorganisms9050915 |
Ejemplares similares
-
Effects of Lactobacillus reuteri supplementation on the gut microbiota in extremely preterm infants in a randomized placebo-controlled trial
por: Martí, Magalí, et al.
Publicado: (2021) -
Low Diversity of Human Milk Oligosaccharides is Associated with Necrotising Enterocolitis in Extremely Low Birth Weight Infants
por: Wejryd, Erik, et al.
Publicado: (2018) -
A protocol for characterization of extremely preterm infant gut microbiota in double-blind clinical trials
por: Martí, Magalí, et al.
Publicado: (2021) -
Pre- and postnatal administration of Lactobacillus reuteri decreases TLR2 responses in infants
por: Forsberg, Anna, et al.
Publicado: (2014) -
Postbiotic Modulation of Retinoic Acid Imprinted Mucosal-like Dendritic Cells by Probiotic Lactobacillus reuteri 17938 In Vitro
por: Haileselassie, Yeneneh, et al.
Publicado: (2016)